Close Menu

Silence

Silence Therapeutics said this week that it plans to raise as much as £5.7 million ($8.8 million) through the issuance of up to around 940 million new ordinary shares.

Silence Therapeutics said this week that it has identified the maximum tolerated dose for its siRNA-based cancer treatment Atu027 and that the drug has proven safe and well-tolerated in a nearly complete phase I trial.

Silence Therapeutics has created a scientific advisory board and named its first two members, Detlef Schuppan and Massimo Pinzani.

Silence Therapeutics last week publicly took issue with Alnylam Pharmaceuticals' claims regarding a European patent opposition, stating that the European Patent Office had limited the “scope and ambiguity” of an Alnylam-controlled patent.

Silence Therapeutics has appointed chief business officer Tony Sedgwick as its new CEO following the resignation of Thomas Christely.

Silence Therapeutics announced this week that it has signed a deal under which Miragen will evaluate its microRNA therapeutic candidates in combination with Silence's cationic lipid-based DBTC delivery technology.

Silence Therapeutics has scored a victory in its efforts to defend its intellectual property estate, announcing this week that the US Patent and Trademark Office has upheld the validity of four patents related to the design of RNAi molecules.

Silence Therapeutics said this week that the European Patent Office has upheld an amended form of a patent covering protein kinase N beta, which is silenced with the company's phase I cancer drug Atu027.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.